Communicable Diseases  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01756508: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Completed
2
57
RoW
eculizumab, Soliris
Russian Academy of Medical Sciences
End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury
04/17
12/17

Download Options